Evidence map›Paper›PMID 30792985›Full record

ReviewERJ open research2019

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Tiago M Alfaro, Catharina C Moor, Veronica Alfieri, Florence Jeny, Michael Kreuter, Marlies S Wijsenbeek, Elisabetta A Renzoni, Elena Bargagli, Hilario Nunes, Paolo Spagnolo and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ERJ open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tiago M AlfaroUnit of Respiratory Medicine A, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.ORCID https://orcid.org/0000-0001-6490-0620
Catharina C MoorDept of Respiratory Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands.
Veronica AlfieriRespiratory Disease and Lung Function Unit, Dept of Medicine and Surgery, University of Parma, Parma, Italy.
Florence JenyAP-HP, Pneumology Dept, Avicenne Hospital, Centre de Référence des Maladies Pulmonaires Rares, Bobigny, France.
Michael KreuterCenter for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany.
Marlies S WijsenbeekDept of Respiratory Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands.
Elisabetta A RenzoniInterstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
Elena BargagliSection of Respiratory Diseases and Lung Transplantation, Dept of Clinical Medicine and Neurosciences, Siena University Hospital, Siena, Italy.
Hilario NunesAP-HP, Pneumology Dept, Avicenne Hospital, Centre de Référence des Maladies Pulmonaires Rares, Bobigny, France.
Paolo SpagnoloSection of Respiratory Diseases, Dept of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
Francesco BonellaInterstitial and Rare Lung Disease Unit, Dept of Pulmonary Medicine, University Hospital - Ruhrlandklinik, Essen, Germany.
Maria Molina-MolinaDept of Pneumology, Bellvitge University Hospital, Barcelona, Spain.
Katerina AntoniouDept of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
Venerino PolettiDept of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy.

Funding

Department of Health PB-PG-0712-28073Versus Arthritis 20719
6 · The paper itself

Abstract

This article reviews a selection of the scientific presentations on interstitial lung disease (ILD)/diffuse parenchymal lung disease (DPLD) that were made at the 2018 European Respiratory Society (ERS) International Congress in Paris. A number of advances in the epidemiology, pathogenesis, diagnosis and treatment of these disorders were presented and discussed by clinicians and researchers. The research topics span over all four groups of ERS Assembly 12: Interstitial Lung Diseases (Group 12.01: Idiopathic interstitial pneumonias; Group 12.02: ILD/DPLD of known origin; Group 12.03: Sarcoidosis and other granulomatous ILD/DPLD; Group 12.04: Rare ILD/DPLD).

Identifiers

PMID30792985
PMCPMC6378342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.